Triple
T6003730
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | leadProductAlsoKnownAs |
P39
|
FINISHED |
| Object |
LOXO-101
LOXO-101 is a targeted cancer therapy drug candidate developed by Loxo Oncology to inhibit TRK fusion proteins implicated in various tumors.
|
E564270
|
NE FINISHED |
Provenance (6 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c00872444c8190bfaf1739dcec765c |
elicitation | completed |
| NER | batch_69c04f0f63148190826198281dce3713 |
ner | completed |
| NED1 | batch_69c1250c82588190af8102263c1bd242 |
ned_source_triple | completed |
| NED2 | batch_69c126070ba08190bc26e61c2c519b50 |
ned_description | completed |
| NEDg | batch_69c125968c70819096266bcf0413a941 |
nedg | completed |
| PD | batch_69c049e3316c819087ea635fa7ee8472 |
pd | completed |
Created at: March 22, 2026, 4:06 p.m.